Altre lingue Regen BioPharma, Inc. OTC Markets

Azioni

RGBPP

US75886M4096

Mercato chiuso - OTC Markets Altri mercati azionari 15:50:16 14/06/2024			Variaz. 5gg	Var. 1 gen.
1,01 ^USD	-19,84%		-19,36%	-57,18%

24/04	Regen BioPharma, Inc. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 31 marzo 2024	CI
09/02	Regen Biopharma, Inc. Deposita una domanda di brevetto provvisorio per accelerare la ricostituzione ematopoietica dopo un insulto o una patologia cronica mediante la somministrazione di cellule progenitrici endoteliali o cellule endoteliali derivate da cellule staminali	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Regen BioPharma : Material Event - Form 8-K	29/04
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	24/04
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	09/02
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024	05/02
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	19/01
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	20/11
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program	14/11
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program	25/10/23
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly	18/10/23
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer	20/09/23
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies	19/09/23
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding	12/09/23
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023	08/08/23
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	25/07/23
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	18/04/23
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	07/02/23
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio	23/01/23
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	19/01/23
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	19/01/23
Regen BioPharma, Inc. Announces Board Appointments	07/12/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Regen BioPharma, Inc. OTC Markets

Azioni

RGBPP

US75886M4096

Altre lingue

Filtri